January 4, 2018 / 12:35 PM / 6 months ago

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

Jan 4 (Reuters) - Audentes Therapeutics Inc:

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

* PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 2018

* TOTAL 6 ADVERSE EVENTS (AES) REPORTED IN ASPIRO, 2 OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS (SAES)

* ‍OF FOUR NON-SERIOUS ADVERSE EVENTS, TWO HAVE BEEN DETERMINED TO BE PROBABLY OR POSSIBLY TREATMENT-RELATED​

* ‍AUDENTES PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below